Preclinical and clinical development of afatinib: A focus on breast cancer and squamous cell carcinoma of the head and neck

Future Oncology

Volumn 10, Issue 1, 2014, Pages 21-40

  Harbeck, Nadia ^a   Solca, Flavio ^b   Gauler, Thomas C ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

afatinib; breast cancer; EGFR; ErbB family; head and neck squamous cell carcinoma; HER2

Indexed keywords

AFATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOPROTEIN; QUINAZOLINE DERIVATIVE;

ADVERSE DRUG REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL EFFECTIVENESS; DRUG DESIGN; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; IN VIVO STUDY; MULTICENTER STUDY (TOPIC); NON SMALL CELL LUNG CANCER; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG SCREENING; FEMALE; HEAD AND NECK NEOPLASMS; LUNG NEOPLASMS; METABOLISM;

ANIMALS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; ONCOGENE PROTEINS V-ERBB; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901326894     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.244     Document Type: Article

References (131)

1. Zhang H, Berezov A, Wang Q et al. ErbB receptors: from oncogenes to targeted cancer therapies. J. Clin. Invest. 117(8), 2051-2058 (2007).
2. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2(2), 127-137 (2001).
3. Lemmon M. Ligand-induced ErbB receptor dimerization. Exp. Cell Res. 315(4), 639-648 (2009).
4. Fry W, Kotelawala L, Sweeney C, Carraway K III. Mechanisms of ErbB receptor negative regulation and relevance in cancer. Exp. Cell Res. 315(4), 697-706 (2009).
5. Garrett TPJ, McKern NM, Lou M et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11(2), 495-505 (2003).
6. Campbell MR, Amin D, Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin. Cancer Res. 16(5), 1373-1383 (2010).
7. Menendez JA, Lupu R. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited? Breast Cancer Res. 9(5), 111 (2007).
8. Nicholson R, Gee J, Harper M. EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4), S9-S15 (2001).
9. Mitsudomi T, Yatabe Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J. 277(2), 301-308 (2010).
10. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14(4), 320-368 (2009).
11. Wykosky J, Fenton T, Furnari F, Cavenee W. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin. J. Cancer 30(1), 5-12 (2011).
12. Adams CW, Allison DE, Flagella K et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol. Immunother. 55(6), 717-727 (2006).
13. Solca F, Dahl G, Zoephel A et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J. Pharmacol. Exp. Ther. 343(2), 342-350 (2012).
14. Eck M, Yun C-H. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim. Biophys. Acta 1804(3), 559-566 (2010).
15. Hammerman P, Jänne P, Johnson B. Resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 15(24), 7502-7509 (2009).
16. Nguyen KS, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin. Lung Cancer 10(4), 281-289 (2009).
17. Sequist LV, Waltman BA, Dias-Santagata D et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
18. Engelman JA, Zejnullahu K, Mitsudomi T et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827), 1039-1043 (2007).
19. Sierra J, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9, 75 (2010).
20. Eskens FA, Mom CH, Planting AS et al. A Phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br. J. Cancer 98(1), 80-85 (2008).
21. Li D, Ambrogio L, Shimamura T et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27(34), 4702-4711 (2008).
22. Giaccone G, Wang Y. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. Cancer Treat. Rev. 37(6), 456-464 (2011).
23. Perera SA, Li D, Shimamura T et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc. Natl Acad. Sci. USA 106(2), 474-479 (2009).
24. Schutze C, Dorfler A, Eicheler W et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther. Onkol. 183(5), 256-264 (2007).
25. Solca F, Adolf G, Jones H, Uttenreuther-Fischer M. Beyond trastuzumab: second-generation targeted therapies for HER-2-positive breast cancer. In: Milestones in Drug Therapy. Sibilia M (Ed.). Springer, Basel, Switzerland, 91-117 (2011).
26. Hickish T, Wheatley D, Lin N et al. Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res. 69(Suppl.), Abstract 5060 (2009).
27. Solca F, Schweifer N, Baum A et al. BIBW 2992, an irreversible dual EGFR/HER2 kinase inhibitor, shows activity on L858R/T790M EGFR mutants. Clin. Cancer Res. 11(23), A242 (2005).
28. Quesnelle KM, Grandis JR. Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance. Clin. Cancer Res. 17(18), 5935-5944 (2011).
29. Bahleda R, Soria J, Bergé Y, Massard C. Phase I trial to assess the safety and pharmacokinetics of afatinib (BIBW 2992) in combination with intravenous weekly vinorelbine in patients with advanced solid tumors. J. Clin. Oncol. 29(Suppl.), Abstract 2585 (2011).
30. Yap TA, Vidal L, Adam J et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J. Clin. Oncol. 28(25), 3965-3972 (2010).
31. da Cunha Santos G, Shepherd F, Tsao M. EGFR mutations and lung cancer. Ann. Rev. Pathol. 6, 49-69 (2011).
32. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12(2), 175-180 (2011).
33. Mazières J, Peters S, Lepage B et al. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 31(16), 1997-2003 (2013).
34. Rosell R, Carcereny E, Gervais R et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase 3 trial. Lancet Oncol. 13(3), 239-246 (2012).
35. Mok TS, Wu YL, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947-957 (2009).
36. Hirsh V. Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncol. 7(7), 817-825 (2011).
37. Miller V, Hirsh V, Cadranel J et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a Phase 2b/3 randomised trial. Lancet Oncol. 13(5), 528-538 (2012).
38. Hirsh V, Cadranel J, Cong XJ et al. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized Phase IIb/III trial (LUX-Lung 1). J. Thorac. Oncol. 8, 229-237 (2013).
39. Murakami H, Tamura T, Takahashi T et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother. Pharmacol. 69(4), 891-899 (2012).
40. Katakami N, Atagi S, Goto K et al. LUX-Lung 4: a Phase II trial of afatinib in patients with advanced, non-small cell lung cancer who progressed on prior treatment with erlotinib, gefitinib, or both. J. Clin. Oncol. 31(27), 3335-3341 (2012).
41. Schuler M, Planchard D, Yang J-H et al. Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator's choice chemotherapy following progression on afatinib monotherapy. J. Clin. Oncol. 30(15), Abstract 7557 (2012).
42. Yang J-H, Shih J-Y, Hsia T-C. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a Phase 2 trial. Lancet Oncol. 13(5), 539-548 (2012).
43. Sequist L, Yang J-H, Yamamoto N et al. Afatinib or cisplatin/pemetrexed in pulmonary adenocarcinoma patients with epidermal growth factor receptor mutations. J. Clin. Oncol. 31(27), 3327-3334 (2012).
44. Pietanza MC, Lynch TJ Jr, Lara PN Jr et al. XL647 - a multitargeted tyrosine kinase inhibitor: results of a Phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J. Thorac. Oncol. 7(1), 219-226 (2012).
45. Johnson ML, Riely GJ, Rizvi NA et al. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J. Thorac. Oncol. 6(6), 1128-1131 (2011).
46. Sequist LV, Besse B, Lynch TJ et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a Phase II trial in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 28(18), 3076-3083 (2010).
47. Janjigian YY, Azzoli CG, Krug LM et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin. Cancer Res. 17(8), 2521-2527 (2011).
48. Lin N, Winer E, Wheatley D et al. A Phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res. Treat. 133(3), 1057-1065 (2012).
49. Seiwert TY, Fayette J, Cupissol D et al. Final results of a randomized, open-label, cross-over Phase II study of afatinib (BIBW 2992) versus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Presented at: Multidisciplinary Head and Neck Cancer Symposium (MHNCS). Phoenix, AZ, USA, 26-28 January 2012 (Abstract 235).
50. Press M, Bernstein L, Thomas P et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J. Clin. Oncol. 15(8), 2894-2904 (1997).
51. Kadcyla®, prescribing information. Genentech, CA, USA (2013).
52. Herceptin®, prescribing information. Genentech, CA, USA (2010).
53. Tykerb®, prescribing information. GlaxoSmithKline, London, UK (2012).
54. Perjeta®, prescribing information. Genentech, CA, USA (2012).
55. Baselga J, Cortes J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366(2), 109-119 (2012).
56. Cobleigh M, Vogel C, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648 (1999).
57. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001).
58. Vogel C, Cobleigh M, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3), 719-726 (2002).
59. Barok M, Isola J, Palyi-Krekk Z et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 6(7), 2065-2072 (2007).
60. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68(22), 9280-9290 (2008).
61. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367(19), 1783-1791 (2012).
62. Swain SM, Kim SB, Cortés J et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, Phase 3 study. Lancet Oncol. 14(6), 461-471 (2013).
63. Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, Phase 2 trial. Lancet Oncol. 13(1), 25-32 (2012).
64. Rusnak D, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1(2), 85-94 (2001).
65. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355(26), 2733-2743 (2006).
66. Cameron D, Casey M, Press M et al. A Phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 112(3), 533-543 (2008).
67. Rana P, Sridhar S. Efficacy and tolerability of lapatinib in the management of breast cancer. Breast Cancer (Auckl.) 6, 67-77 (2012).
68. Johnston S, Pippen J Jr, Pivot X et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27(33), 5538-5546 (2009).
69. Baselga J, Bradbury I, Eidtmann H et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, Phase 3 trial. Lancet 379(9816), 633-640 (2012).
70. Blackwell K, Burstein H, Storniolo A et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 study. J. Clin. Oncol. 30(21), 2585-2592 (2012).
71. Rabindran SK, Discafani CM, Rosfjord EC et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res. 64(11), 3958-3965 (2004).
72. Tsou HR, Overbeek-Klumpers EG, Hallett WA et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 48(4), 1107-1131 (2005).
73. Burstein H, Sun Y, Dirix L et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28(8), 1301-1307 (2010).
74. Arribas J. p95HER2 and breast cancer. Cancer Res. 71(5), 1515-1519 (2011).
75. Wong A, Lee S. Mechanisms of resistance to trastuzumab and novel therapeutic strategies in HER2-positive breast cancer. Int. J. Breast Cancer 2012, 415170 (2012).
76. Nahta R, Esteva F. Herceptin: mechanisms of action and resistance. Cancer Lett. 232(2), 123-138 (2006).
77. Blackwell K, Burstein H, Storniolo A et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28(7), 1124-1130 (2010).
78. Marshall J, Hwang J, Eskens FA et al. A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors. Invest. New Drugs 31(2), 399-408 (2013).
79. Gordon MS, Mendelson DS, Gross M et al. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest. New Drugs 31(2), 409-416 (2013).
80. Awada AH, Dumez H, Hendlisz A et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest. New Drugs 31(3), 734-741 (2013).
81. Rimawi M, Aleixo S, Rozas A, Neto J. A neoadjuvant, randomized, open-label Phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC). J. Clin. Oncol. 30(15 Suppl.), Abstract 606 (2012).
82. Schuler M, Awada A, Harter P et al. A Phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res. Treat. 134(3), 1149-1159 (2012).
83. Gunzer K, de Mont-Serrat H, Uttenreuther-Fischer M, Misset J. Addition of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2, to letrozole in estrogen receptor (ER)-positive metastatic breast cancer (mBC) progressing on letrozole monotherapy. J. Clin. Oncol. 28(15 Suppl.), Abstract 1072 (2010).
84. Swanton C, Cromer J; 1200.89 Study Group. Open-label, Phase II trial of afatinib, with or without vinorelbine (V), for the treatment of HER2-overexpressing inflammatory breast cancer (IBC). J. Clin. Oncol. 30(15 Suppl.), Abstract TPS650 (2012).
85. Harbeck N, Im S, Huang C-S et al. LUX-Breast 1: randomized, Phase III trial of afatinib and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment. J. Clin. Oncol. 30(15 Suppl.), Abstract TPS649 (2012).
86. Hickish T, Tseng L-M, Mehta A et al. LUX-Breast 2: Phase II, open-label study of oral afatinib in HER2-overexpressing metastatic breast cancer (MBC) patients (pts) who progressed on prior trastuzumab (T) and/or lapatanib (L). J. Clin. Oncol. 30(15 Suppl.), Abstract TPS651 (2012).
87. Joensuu H, Kaci M. LUX-Breast 3: randomized Phase II study of afatinib alone or with vinorelbine versus investigator's choice of treatment in patients (pts) with HER2-positive breast cancer (BC) with progressive brain metastases (BM) after trastuzumab or lapatinib-based therapy. J. Clin. Oncol. 30(15 Suppl.), Abstract TPS647 (2012).
88. Grégoire V, Lefebvre J, Licitra L, Felip E; Group E-E-EGW. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 21(Suppl. 5), v184-v186 (2010).
89. Seiwert T, Salama J, Vokes E. The chemoradiation paradigm in head and neck cancer. Nat. Clin. Pract. Oncol. 4(3), 156-171 (2007).
90. Agulnik M. New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN). Med. Oncol. 29(4), 2481-2491 (2012).
91. Reuter C, Morgan M, Eckardt A. Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck. Br. J. Cancer 96(3), 408-416 (2007).
92. Chen L, Cohen E, Grandis J. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res. 16(9), 2489-2495 (2010).
93. Sok J, Coppelli F, Thomas S et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res. 12(17), 5064-5073 (2006).
94. Chau NG, Perez-Ordonez B, Zhang K et al. The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol. 3, 11 (2011).
95. Hama T, Yuza Y, Saito Y et al. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14, 900-908 (2009).
96. Erbitux®, prescribing information. Bristol-Myers Squibb/Eli Lilly, NY, USA (2012).
97. Erbitux®. Summary of Product Characteristics. Merck Serono, Middlesex, UK (2012).
98. Vermorken J, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359(11), 1116-1127 (2008).
99. Machiels J, Subramanian S, Ruzsa A et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised Phase 3 trial. Lancet Oncol. 12(4), 333-343 (2011).
100. Vermorken JB, Stoehlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label Phase 3 randomised trial. Lancet Oncol. 14, 697-710 (2013).
101. Ang K, Harris J, Wheeler R, Weber R, Rosenthal D. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24-35 (2010).
102. Chung C, Gillison M. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin. Cancer Res. 15(22), 6758-6762 (2009).
103. Gillison M, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J. Natl Cancer Inst. 100, 407-420 (2008).
104. Psyrri A, Licitra L, De Blas B, Celik I, Vermorken J. Safety and efficacy of cisplatin plus 5-FU and cetuximab in HPV-positive and HPV-negative recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the Phase III EXTREME trial. Ann. Oncol. 23(Suppl. 9), Abstract 10180 (2012).
105. Stewart J, Cohen E, Licitra L et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J. Clin. Oncol. 27(11), 1864-1871 (2009).
106. de Souza J, Davis D, Zhang Y et al. A Phase II study of lapatinib in recurrent/metastatic squamous cell carcinoma of the head and neck. Clin. Cancer Res. 18(8), 2336-2343 (2012).
107. Soulieres D, Senzer N, Vokes E, Hidalgo M, Agarwala S, Siu L. Multicenter Phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22(1), 77-85 (2004).
108. Cohen E, Davis D, Karrison T et al. Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a Phase I/II study. Lancet Oncol. 10(3), 247-257 (2009).
109. Kim E, Kies M, Glisson B et al. Final results of a Phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer. J. Clin. Oncol. 25(18 Suppl.), Abstract 6013 (2007).
110. Vermorken J, Rottey S, Ehrnrooth E, Pelling K. 1204 ORAL A Phase lb open-label study to assess continuous oral treatment with afatinib (BIBW 2992) in combination with two chemotherapy regimens - cisplatin plus paclitaxel, and cisplatin plus 5-fluorouracil in patients, with advanced solid tumours. Eur. J. Cancer 47(Suppl. 1), S145 (2011).
111. Cupissol D, Seiwert TY, Fayette J et al. A randomized, open-label, Phase II study of afatinib vs cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of stage 2 (S2) following crossover. J. Clin. Oncol. 31 (Suppl.), Abstract 6001 (2013).
112. Seiwert TY, Fayette J, Cupissol D et al. A randomized, open-label, Phase II study of afatinib vs cetuximab in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). Ann. Oncol. 23(Suppl. 11), xi35-xi36 (2012).
113. Machiels J-P, Licitra L, Haddad R, Tahara M, Svensson L, Cong X. LUX-H&N 1: a Phase III, randomized trial of afatinib versus methotrexate (MTX) in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy. J. Clin. Oncol. 30(15 Suppl.), Abstract TPS5598 (2012).
114. Burtness B, Bourhis J, Vermorken J, Dai L, Lind C, Ehrnrooth E. LUX Head and Neck 2: a randomized, double-blind, placebo-controlled, Phase III study of afatinib as adjuvant therapy after chemoradiation in primarily unresected, clinically high-risk, head and neck cancer patients. J. Clin. Oncol. 30(15 Suppl.), Abstract TPS5599 (2012).
115. Ku GY, Haaland BA, de Lima Lopes G Jr. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of Phase III trials. Lung Cancer 74, 469-473 (2011).
116. Yang JC-H, Reguart N, Barinoff J et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert. Rev. Anticancer Ther. 13(6), 729-736 (2013).
117. Lacouture M, Schadendorf D, Chu C-Y et al. Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert. Rev. Anticancer Ther. 13(6), 721-728 (2013).
118. Spicer J, Harris D, Ang J et al. A Phase I study of daily BIBW 2992, an irreversible EGFR/HER2 dual kinase inhibitor, in combination with weekly paclitaxel. Ann. Oncol. 19, Abstract 474 (2008).
119. ClinicalTrials.gov. LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy. http://clinicaltrials.gov/ct2/show/NCT01523587?term=NCT01523587&rank=1 (Accessed 6 February 2013)
120. ClinicalTrials.gov. BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC). http://clinicaltrials.gov/ct2/show/NCT01121393 (Accessed 6 February 2013)
121. ClinicalTrials.gov. LUX-Lung 7: A Phase IIb Trial of Afatinib (BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung. http://clinicaltrials.gov/ct2/show/NCT01466660?term=NCT01466660&rank=1 (Accessed 6 February 2013)
122. US FDA. FDA approves new treatment for late-stage breast cancer. 22 February 2013. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340704.htm (Accessed 27 February 2013)
123. US FDA. FDA approves Perjeta for type of late-stage breast cancer. 8 June 2012. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm307549.htm (Accessed 27 February 2013)
124. ClinicalTrials.gov. ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. http://clinicaltrials.gov/ct2/show/NCT00490139?term=altto&rank=1 (Accessed 6 February 2013)
125. ClinicalTrials.gov. Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer (NEFERTT). http://clinicaltrials.gov/ct2/show/NCT00915018?term=NEFERTT&rank=1 (Accessed 6 February 2013)
126. ClinicalTrials.gov. Neratinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT01670877 (Accessed 27 February 2013)
127. ClinicalTrials.gov. Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT01111825?term=neratinib+AND+HER2+negative&rank=1 (Accessed 27 February 2013)
128. ClinicalTrials.gov. Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer (ExteNET). http://clinicaltrials.gov/ct2/show/NCT00878709?term=ExteNET&rank=1 (Accessed 6 February 2013)
129. Puma Biotechnology. Puma Biotechnology announces agreement with FDA on special protocol assessment for Phase III trial of PB272 (Neratinib) in HER2-positive metastatic breast cancer patients. 20 February 2013. www.pumabiotechnology.com/pr20130220.html (Accessed 27 February 2013)
130. ClinicalTrials.gov. Afatinib (BIBW2992) In HER2-Overexpressing Inflammatory Breast Cancer. http://clinicaltrials.gov/ct2/show/NCT01325428?term=afatinib+AND+inflammatory&rank=1 (Accessed 27 February 2013)
131. ClinicalTrials.gov. Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery. http://clinicaltrials.gov/ct2/show/NCT00424255?term=NCT00424255&rank=1 (Accessed 6 February 2013)